Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6157057 | 0.82 | RAB9A (0.52) | SMN1; SMN2ALDH1A1LMNAKDM4ERAB9A | |
| SCHEMBL6157321 | 0.81 | KDM4E (0.51) | SMN1; SMN2ALDH1A1LMNAKDM4ERAB9A | |
| SCHEMBL7488315 | 0.69 | KDM4E (0.43) | SMN1; SMN2KDM4ERAB9AMAPTGAA | |
| SCHEMBL16838755 | 0.69 | ALDH1A1 (0.61) | SMN1; SMN2ALDH1A1LMNAKDM4ERAB9A | |
| SCHEMBL9570224 | 0.69 | PDE10A (0.50) | SMN1; SMN2ALDH1A1KDM4ERAB9AMAPT | |
| SCHEMBL4888453 | 0.69 | MAPT (0.41) | ALDH1A1LMNAKDM4ERAB9AMAPT | |
| SCHEMBL5383075 | 0.68 | RAB9A (0.40) | SMN1; SMN2LMNAKDM4ERAB9AMAPT | |
| SCHEMBL6602394 | 0.68 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1LMNAKDM4ERAB9A | |
| SCHEMBL5377275 | 0.68 | RAB9A (0.39) | SMN1; SMN2LMNAKDM4ERAB9AMAPT | |
| SCHEMBL16838753 | 0.67 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1LMNAKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924300-B2 | Oxyiminoalkanoic acid derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| EP-1077957-B1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-08-04 | — | — | EP | disclosed |
| EP-1428531-A1 | Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-20030186985-A1 | Oxyiminoalkanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| US-6495581-B1 | DRUG FOR TREATING DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE, ARTERIAL SCLEROSIS AND IMPROVING INSULIN RESISTANCE, INFLAMMATORY DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| US-6251926-B1 | OXYIMINOALKANOIC ACID DERIVATIVES HAVING HYPOGLYCEMIC EFFECT AND HYPOLIPIDEMIC EFFECT, IS USEFUL FOR TREATMENT OF DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE INFLAMMATORY DISEASE AND ARTERIOSCLEROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186985-A1 | Oxyiminoalkanoic acid derivatives | GPR119, IRS1, CPT1A | SMN1; SMN2 3404/4885ALDH1A1 2409/4885LMNA 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.